- Home
- TARS vs CUBI Comparison
TARS vs CUBI Comparison
Compare TARS & CUBI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | TARS | CUBI |
|---|---|---|
| Founded | 2016 | 1994 |
| Country | United States | United States |
| Employees | N/A | 790 |
| Industry | Medicinal Chemicals and Botanical Products | Major Banks |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.7B | 2.4B |
| IPO Year | 2020 | N/A |
Fundamental Metrics
Financial Performance| Metric | TARS | CUBI |
|---|---|---|
| Price | $66.39 | $67.51 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 6 | 8 |
| Target Price | ★ $89.00 | $86.63 |
| AVG Volume (30 Days) | ★ 403.1K | 368.1K |
| Earning Date | 04-30-2026 | 04-23-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 48.21 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $451,360,000.00 | N/A |
| Revenue This Year | $55.67 | $24.99 |
| Revenue Next Year | $30.64 | $9.66 |
| P/E Ratio | ★ N/A | $11.78 |
| Revenue Growth | ★ 146.71 | N/A |
| 52 Week Low | $38.51 | $40.75 |
| 52 Week High | $85.25 | $82.56 |
Technical Indicators
Market Signals| Indicator | TARS | CUBI |
|---|---|---|
| Relative Strength Index (RSI) | 43.79 | 45.22 |
| Support Level | $65.62 | $64.65 |
| Resistance Level | $67.70 | $69.63 |
| Average True Range (ATR) | 2.75 | 1.91 |
| MACD | -0.44 | 0.52 |
| Stochastic Oscillator | 39.31 | 58.78 |
Price Performance
Historical ComparisonAbout TARS Tarsus Pharmaceuticals Inc.
Tarsus Pharmaceuticals Inc is a commercial-stage biopharmaceutical company focused on the development and commercialization of therapeutics, starting with eye care. The company is focused on the development and commercialization of first-in-class therapeutic candidates to provide treatment for ophthalmic conditions. The company's candidate XDEMVY is a novel investigational eye drop to treat blepharitis caused by the infestation of Demodex mites, referred to as Demodex blepharitis. TP-04 for the potential treatment of ocular rosacea and TP-05 for potential Lyme disease prophylaxis and community malaria reduction.
About CUBI Customers Bancorp Inc
Customers Bancorp Inc is a bank holding company engaged in banking activities. It provides financial products and services to small and middle-market businesses, not-for-profits, and consumers. The company operates in Lending Activities, Commercial Lending, Consumer Lending, Private Banking, Deposit Products, Other Funding Sources and Financial Products and Services. The majority of revenue is derived from commercial lending.